Biogen is a biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological diseases. Its core products include treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Major business segments encompass neuroscience and rare diseases, with primary revenue sources derived from product sales and royalties. The company is recognized for its research and development efforts in the healthcare sector.
The investment profile of Biogen is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income. Its moderate volatility suggests a balanced risk approach, suitable for investors with a medium to long-term horizon.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-09 | Buy | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-08-14 | Hold | Buy | Strong fundamentals and positive momentum support growth outlook. |
| 2026-08-04 | Buy | Hold | Mixed momentum; fundamentals show promise but uncertainty remains. |
| 2026-07-14 | Sell | Buy | Strong momentum and solid earnings growth support investment. |
| 2026-07-09 | Buy | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-06-25 | Hold | Buy | Strong fundamentals and positive momentum support growth outlook. |
| 2026-06-17 | Buy | Hold | Strong fundamentals, but mixed momentum signals present uncertainty. |
| 2026-05-28 | Hold | Buy | Strong EPS growth and positive momentum indicators. |
| 2026-05-20 | Buy | Hold | Mixed performance; cautious outlook amid market uncertainty. |
| 2026-05-08 | — | Buy | Strong EPS growth and positive momentum indicators. |
| 2026-05-08 | Hold | Hold | Компания демонстрирует положительную динамику выручки и EPS, а также значительный рост за последние 120 дней. Учитывая текущие показатели и потенциал роста, инвестиции в Biogen выглядят привлекательными. |
| 2026-02-06 | Buy | Hold | Компания Biogen демонстрирует сильный рост на длительных интервалах, что указывает на позитивные перспективы. Несмотря на недавние колебания, долгосрочные тренды и Momentum подтверждают привлекательность акций. |
| 2026-01-27 | Hold | Buy | Компания показывает сильный рост за последние 60 и 120 дней, что свидетельствует о положительной динамике. Несмотря на недоступность некоторых финансовых показателей, текущая цена и тренды указывают на возможность дальне |
| 2026-01-25 | Buy | Hold | Компания Biogen демонстрирует положительную динамику на длительных горизонтах, однако недавние колебания цен и отсутствие данных по EPS и выручке вызывают определенные риски. |
| 2026-01-22 | Hold | Buy | Компания Biogen показывает сильный рост за последние 60 и 120 дней, что свидетельствует о положительной динамике. Несмотря на недавние колебания, перспективы остаются оптимистичными. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-03 | Piper Sandler | Target Raised | 225 → 245 | 222.67 |
| 2026-08-25 | RBC Capital | Target Raised | 240 → 260 | 218.12 |
| 2026-08-13 | Wolfe Research | Rating Upgraded | — → 300 | 208.87 |
| 2026-07-30 | Morgan Stanley | Target Raised | 222 → 231 | 206.5 |
| 2026-07-30 | H.C. Wainwright | Target Raised | 237 → 251 | 205.735 |
| 2026-07-30 | RBC Capital | Target Lowered | 242 → 240 | 204.1 |
| 2026-07-30 | UBS | Target Raised | 225 → 240 | 204.62 |
| 2026-07-30 | Canaccord Genuity | Target Raised | 245 → 248 | 209.23 |
| 2026-07-29 | Oppenheimer | Update | — → 300 | 209.23 |
| 2026-07-21 | Guggenheim | Target Raised | 260 → 280 | 203.025 |
| 2026-07-13 | Wedbush | Target Raised | 196 → 201 | 202.045 |
| 2026-07-13 | Truist Financial | Rating Upgraded | — → 235 | 199.15 |
| 2026-07-08 | Morgan Stanley | Target Lowered | 224 → 222 | 205.7 |
| 2026-07-07 | RBC Capital | Target Raised | 227 → 242 | 208.46 |
| 2026-07-06 | HSBC | Target Raised | 150 → 157 | 213.2607 |
| 2026-06-18 | Morgan Stanley | Target Raised | 206 → 224 | 198.67 |
| 2026-06-15 | Mizuho Securities | Target Lowered | 236 → 221 | 200.05 |
| 2026-06-08 | Needham | Rating Upgraded | — → 255 | 195.34 |
| 2026-05-27 | RBC Capital | Target Raised | — → 227 | 193.08 |
| 2026-05-15 | Piper Sandler | Target Raised | 214 → 225 | 191.37 |
| 2026-04-30 | Morgan Stanley | Target Raised | 200 → 206 | 188.7563 |
| 2026-04-30 | RBC Capital | Target Raised | 213 → 222 | 190.7767 |
| 2026-04-30 | Wedbush | Target Raised | 191 → 196 | 194.38 |
| 2026-04-30 | Guggenheim | Target Raised | 246 → 260 | 194.38 |
| 2026-04-20 | Wells Fargo | Rating Upgraded | — → 250 | 177.35 |
| 2026-04-14 | Piper Sandler | Rating Upgraded | — → 214 | 176.365 |
| 2026-04-10 | Morgan Stanley | Target Raised | 190 → 200 | 173.482 |
| 2026-02-19 | Barclays | Update | — → 185 | 192.08 |
| 2026-02-11 | Mizuho Securities | Target Raised | 207 → 236 | 188.99 |
| 2026-02-10 | Wedbush | Target Raised | 178 → 187 | 192.715 |
| 2026-02-09 | Wolfe Research | Update | — → 231 | 195.995 |
| 2026-02-09 | RBC Capital | Target Raised | 217 → 233 | 195.93 |
| 2026-02-09 | Wolfe Research | Target Raised | — → 215 | 195.45 |
| 2026-02-09 | Truist Financial | Target Raised | 190 → 193 | 201.18 |
